Struggling Arena Pharma axes 80 jobs, narrows R&D

Just a couple of weeks after booting company co-founder and CEO Jack Lief out of the company, a struggling Arena Pharmaceuticals ($ARNA) has followed up with a move to ax 35% of its staff--some 80 jobs--while narrowing its R&D focus. Arena has been losing market share with its obesity drug Belviq, which has proved to be a troublesome therapy to market. The focus at Arena now will be on "near-term" activities. Company shares are down 8% this morning. More cuts are also on the way. Release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.